Niagen Bioscience (NAGE) Income from Continuing Operations (2010 - 2026)
Niagen Bioscience's (NAGE) quarterly Income from Continuing Operations came in at 6318000.0 in Q1 2026, up 24.79% year-on-year from 5063000.0 in Q1 2025, and up 52.9% on a QoQ basis from 4132000.0 in Q4 2025.
Niagen Bioscience (NAGE) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 17 years of Income from Continuing Operations data on file, last reported at 6318000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 24.79% year-over-year to 6318000.0 in Q1 2026; TTM through Mar 2026 was 18637000.0, a 32.13% increase from a year earlier, with the FY2025 full-year figure at 17382000.0, up 103.3% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 6318000.0, up from 4132000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for NAGE reached as high as 7179000.0 in Q4 2024 and fell as low as 11657000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 968352.94 across 5 years, with a median of 270000.0 in 2023.
- On a YoY basis, Income from Continuing Operations climbed as much as 24160.0% in 2025 and fell as far as 42.44% in 2025.
- Year by year, Income from Continuing Operations stood at 1579000.0 in 2022, then jumped by 82.9% to 270000.0 in 2023, then soared by 2758.89% to 7179000.0 in 2024, then sank by 42.44% to 4132000.0 in 2025, then soared by 52.9% to 6318000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 6318000.0 in Q1 2026, 4132000.0 in Q4 2025, and 4578000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Niagen Bioscience | 253.47 Mn | 186.92 Mn | 19.98 Mn | 6.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.32 Mn |
| Dec 31, 2025 | 4.13 Mn |
| Sep 30, 2025 | 4.58 Mn |
| Jun 30, 2025 | 3.61 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Dec 31, 2024 | 7.18 Mn |
| Sep 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | -492,000.00 |
| Dec 31, 2023 | -270,000.00 |
| Sep 30, 2023 | -5.39 Mn |
| Jun 30, 2023 | -6.79 Mn |
| Mar 31, 2023 | -6.68 Mn |
| Dec 31, 2022 | -1.58 Mn |
| Sep 30, 2022 | -8.11 Mn |
| Jun 30, 2022 | -11.66 Mn |
| Mar 31, 2022 | -8.23 Mn |
| Dec 31, 2021 | -4.85 Mn |
| Sep 30, 2021 | -9.68 Mn |
| Jun 30, 2021 | -9.68 Mn |